RPN2 and breast carcinoma: This type of RPN2-mediated glycosylation of p-gp (encoded by MDR1) is responsible for the treatment resistance of several tumors, including breast cancer, ovarian cancer, gastric cancer, and esophageal squamous cell carcinoma9–12.